Trametinib
Tier C — Watch / tradeTrametinib · all drugs expiring in 2029 →
Targets：MEK2, MEK1
Brand：Mecinist, Mekinist, Meqsel, Mekinisuto, Spexotras, Tasu Mekinisuto
Indications (approved)：Thyroid cancer, Glioma, Hairy cell leukaemia, Anaplastic thyroid cancer, Solid tumour, Non-small cell lung cancer, Melanoma
Regional status
Factories producing this API1
Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.
1 producing factories on file — sign in to view the named list (factory details are not shown to guests).
Sign in to view factories →Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| TRAT-001 | 29632-74-4Available | 2-fluoro-4-iodoaniline |
| TRAT-002 | 86483-52-5Available | cyclopropanamine |
| TRAT-003 | 871700-18-4 | 1-cyclopropyl-3-(2-fluoro-4-iodophenyl)urea |
| TRAT-004 | 372-09-8Available | 2-cyanoacetic acid |
| TRAT-005 | 871700-26-4 | 2-cyano-N-cyclopropyl-N-((2-fluoro-4-iodophenyl)carbamoyl)acetamide |
| TRAT-006 | 871700-28-6Available | 6-amino-3-cyclopropyl-1-(2-fluoro-4-iodophenyl)pyrimidine-2,4(1H,3H)-dione |
| TRAT-007 | 871700-30-0 | (E)-N'-(1-cyclopropyl-3-(2-fluoro-4-iodophenyl)-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-N,N-dimethylformimidamide |
| TRAT-008 | 871700-22-0Available | 3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6-(methylamino)pyrimidine-2,4(1H,3H)-dione |
| TRAT-009 | 516-05-2 | 2-methylmalonic acid |
| TRAT-010 | 871700-24-2Available | 3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-5-hydroxy-6,8-dimethylpyrido[2,3-d]pyrimidine-2,4,7(1H,3H,8H)-trione |
| TRAT-011 | 871700-32-2 | 3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxo-1,2,3,4,7,8-hexahydropyrido[2,3-d]pyrimidin-5-yl 4-methylbenzenesulfonate |
| TRAT-012 | 102-28-3 | N-(3-aminophenyl)acetamide |
| TRAT-013 | 871700-25-3 | N-(3-((3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxo-1,2,3,4,7,8-hexahydropyrido[2,3-d]pyrimidin-5-yl)amino)phenyl)acetamide |
Frequently asked questions
What are the approved indications of Trametinib?
Approved indications include: Thyroid cancer, Glioma, Hairy cell leukaemia, Anaplastic thyroid cancer, Solid tumour, Non-small cell lung cancer, Melanoma.
When does the Trametinib patent expire?
Based on public sources, the Trametinib patent expires in 2029.
How many synthesis routes are recorded for Trametinib?
1 synthesis routes are recorded; the shortest is 10 steps with 8.3 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Trametinib intermediates?
6 intermediate CAS of Trametinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Trametinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29